fda decision about compound tirzepatide shortage is on list 🚨 Alert: Tirzepatide No Longer on FDA's Drug Shortage List As FDA Affirms on Tirzepatide – FDA says compounding pharmacies can

Patients taking insulin or certain diabetes medications face higher hypoglycemia risk when starting semaglutide, since the compound reduces blood sugar through multiple pathways simultaneously

Regardless of which GLP-1 medication your employees are taking, there is also an avenue for them to save money by applying for the Manufacturer's Patient Assistance Program (PAP)

This phenomenon, sometimes called tolerance or dose creep, is reported anecdotally with tirzepatide, though the clinical trial data does not show significant tolerance development at fixed doses over 72 weeks

They can create a safe plan to either switch medications or adjust your therapy